Aura Renew Acq Regulatory News (ARA)

29 Jun 2006 07:01

Ardana PLC29 June 2006 ARDANA APPOINTS NEW NON-EXECUTIVE TO THE BOARD Edinburgh, UK, 29 June, 2006; Ardana, the company focused on improving humanreproductive health, today announces that Huw Jones has been appointed as anon-executive director. Huw Jones was awarded a PhD in Pharmacology 1986. After a short period ofpostdoctoral research, he joined Smith Kline & French UK in a commercial role in1986. During his eleven-year career at SK&F and SmithKline Beecham he migratedthrough a number of sales, marketing, business development and new productdevelopment roles of increasing seniority. He was appointed UK MarketingDirector in 1996. Huw moved to Elan Corporation PLC in 1997. In 1998 he was appointedVice-President and Managing Director, UK and in 2001 was appointed Senior VicePresident, Northern Europe, responsible for operations in Germany, France,Ireland, the UK and for establishing companies in Benelux. In 2002 he co-founded Daffodil Consulting LLP which specialises in providingstrategic advice on Europe to biopharmaceutical companies. Daffodil Consultingwas asked to establish the European affiliate for CV Therapeutics Inc (NASDAQ,CVTX) in late 2002. Huw served as President, Europe, for CV Therapeutics between2002 and 2006. He is also Non-Executive Chairman of Ashbourne Pharmaceuticals. Maureen Lindsay, CEO of Ardana, said: "Huw brings considerable sales and marketing expertise to our Board and we aredelighted that he is joining us. He has an impressive background and his currentdirectorships demonstrate how highly he is valued in an advisory capacity. Hiscontributions will be invaluable as we grow our commercial product pipelineacross Europe." For more information contact: Ardana Financial DynamicsMaureen Lindsay (corporate/financial media relations)Tel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert Tel: +44 (0)20 7831 3113 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andoutlicensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • StriantTM SR, a testosterone replacement therapy that has already been launched by Ardana through its own sales force in the UK as a treatment for men with hypogonadism and for which Ardana has marketing rights in Europe; • Teverelix LA, in development for three initial indications (prostate cancer, BPH and endometriosis); • Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, and is in Phase II trials; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe. In addition, Ardana has a strong portfolio of follow-on products in development. Ardana is listed on the Main Market of the London Stock Exchange. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange